// Cardiovascular System - Drugs
// Auto-generated from modularize-data.js

const drugs = [

    {
        "id": "lisinopril",
        "name": "Lisinopril",
        "pharmacologicClass": "ace-inhibitors",
        "therapeuticClass": "antihypertensives",
        "system": "cardiovascular-system",
        "mechanism": "Inhibit Angiotensin Converting Enzyme, reducing Angiotensin II and causing vasodilation.",
        "features": "Long half-life, not a prodrug.",
        "clinicalChoice": "First-line for hypertension, especially in diabetics.",
        "indications": [
            "Hypertension",
            "Heart Failure",
            "Diabetic Nephropathy"
        ],
        "contraindications": [
            "Pregnancy",
            "History of Angioedema"
        ],
        "sideEffects": [
            "Dry cough",
            "Angioedema",
            "Hyperkalemia"
        ],
        "interactions": "Potassium-sparing diuretics, NSAIDs.",
        "interactionDetails": "POTASSIUM-SPARING DIURETICS: MECHANISM - ACE inhibitors reduce aldosterone production (via decreased Angiotensin II), leading to potassium retention. Potassium-sparing diuretics independently block aldosterone receptors or epithelial sodium channels, also causing potassium retention. CONSEQUENCE - Additive hyperkalemia can cause dangerous cardiac arrhythmias, including fatal ventricular arrhythmias and asystole. NSAIDS: MECHANISM - ACE inhibitors work partly through increased prostaglandin E2 and prostacyclin (vasodilators). NSAIDs block cyclooxygenase, reducing these protective prostaglandins. CONSEQUENCE - Reduced antihypertensive efficacy and increased risk of acute kidney injury, especially in patients with pre-existing renal disease, elderly patients, or volume-depleted states.",
        "pageType": "drug"
    },
    {
        "id": "captopril",
        "name": "Captopril",
        "pharmacologicClass": "ace-inhibitors",
        "therapeuticClass": "antihypertensives",
        "system": "cardiovascular-system",
        "mechanism": "Inhibit Angiotensin Converting Enzyme, reducing Angiotensin II and causing vasodilation.",
        "features": "Short half-life, contains sulfhydryl group.",
        "clinicalChoice": "Hypertensive emergencies, renal crisis.",
        "indications": [
            "Hypertension",
            "Scleroderma Crisis"
        ],
        "contraindications": [
            "Pregnancy",
            "History of Angioedema"
        ],
        "sideEffects": [
            "Dry cough",
            "Angioedema",
            "Hyperkalemia"
        ],
        "interactions": "Potassium-sparing diuretics, NSAIDs.",
        "interactionDetails": "POTASSIUM-SPARING DIURETICS: MECHANISM - ACE inhibitors reduce aldosterone production (via decreased Angiotensin II), leading to potassium retention. Potassium-sparing diuretics independently block aldosterone receptors or epithelial sodium channels, also causing potassium retention. CONSEQUENCE - Additive hyperkalemia can cause dangerous cardiac arrhythmias, including fatal ventricular arrhythmias and asystole. NSAIDS: MECHANISM - ACE inhibitors work partly through increased prostaglandin E2 and prostacyclin (vasodilators). NSAIDs block cyclooxygenase, reducing these protective prostaglandins. CONSEQUENCE - Reduced antihypertensive efficacy and increased risk of acute kidney injury, especially in patients with pre-existing renal disease, elderly patients, or volume-depleted states.",
        "pageType": "drug"
    },
    {
        "id": "enalapril",
        "name": "Enalapril",
        "pharmacologicClass": "ace-inhibitors",
        "therapeuticClass": "antihypertensives",
        "system": "cardiovascular-system",
        "mechanism": "Inhibit Angiotensin Converting Enzyme, reducing Angiotensin II and causing vasodilation.",
        "features": "Prodrug, proven mortality benefit.",
        "clinicalChoice": "Heart failure with mortality benefit.",
        "indications": [
            "Hypertension",
            "Heart Failure"
        ],
        "contraindications": [
            "Pregnancy",
            "History of Angioedema"
        ],
        "sideEffects": [
            "Dry cough",
            "Angioedema",
            "Hyperkalemia"
        ],
        "interactions": "Potassium-sparing diuretics, NSAIDs.",
        "interactionDetails": "POTASSIUM-SPARING DIURETICS: MECHANISM - ACE inhibitors reduce aldosterone production (via decreased Angiotensin II), leading to potassium retention. Potassium-sparing diuretics independently block aldosterone receptors or epithelial sodium channels, also causing potassium retention. CONSEQUENCE - Additive hyperkalemia can cause dangerous cardiac arrhythmias, including fatal ventricular arrhythmias and asystole. NSAIDS: MECHANISM - ACE inhibitors work partly through increased prostaglandin E2 and prostacyclin (vasodilators). NSAIDs block cyclooxygenase, reducing these protective prostaglandins. CONSEQUENCE - Reduced antihypertensive efficacy and increased risk of acute kidney injury, especially in patients with pre-existing renal disease, elderly patients, or volume-depleted states.",
        "pageType": "drug"
    },
    {
        "id": "ramipril",
        "name": "Ramipril",
        "pharmacologicClass": "ace-inhibitors",
        "therapeuticClass": "antihypertensives",
        "system": "cardiovascular-system",
        "mechanism": "Inhibit Angiotensin Converting Enzyme, reducing Angiotensin II and causing vasodilation.",
        "features": "Long half-life, cardiovascular protection.",
        "clinicalChoice": "Stroke prevention, cardiovascular protection.",
        "indications": [
            "Hypertension",
            "Stroke Prevention"
        ],
        "contraindications": [
            "Pregnancy",
            "History of Angioedema"
        ],
        "sideEffects": [
            "Dry cough",
            "Angioedema",
            "Hyperkalemia"
        ],
        "interactions": "Potassium-sparing diuretics, NSAIDs.",
        "interactionDetails": "POTASSIUM-SPARING DIURETICS: MECHANISM - ACE inhibitors reduce aldosterone production (via decreased Angiotensin II), leading to potassium retention. Potassium-sparing diuretics independently block aldosterone receptors or epithelial sodium channels, also causing potassium retention. CONSEQUENCE - Additive hyperkalemia can cause dangerous cardiac arrhythmias, including fatal ventricular arrhythmias and asystole. NSAIDS: MECHANISM - ACE inhibitors work partly through increased prostaglandin E2 and prostacyclin (vasodilators). NSAIDs block cyclooxygenase, reducing these protective prostaglandins. CONSEQUENCE - Reduced antihypertensive efficacy and increased risk of acute kidney injury, especially in patients with pre-existing renal disease, elderly patients, or volume-depleted states.",
        "pageType": "drug"
    },
    {
        "id": "losartan",
        "name": "Losartan",
        "pharmacologicClass": "angiotensin-receptor-blockers",
        "therapeuticClass": "antihypertensives",
        "system": "cardiovascular-system",
        "mechanism": "Block AT1 receptors, preventing angiotensin II effects without affecting bradykinin.",
        "features": "First ARB, active metabolite.",
        "clinicalChoice": "ACE inhibitor alternative, cough intolerance.",
        "indications": [
            "Hypertension",
            "Diabetic Nephropathy"
        ],
        "contraindications": [
            "Pregnancy"
        ],
        "sideEffects": [
            "Hyperkalemia",
            "Hypotension",
            "Dizziness"
        ],
        "interactions": "Potassium-sparing diuretics, NSAIDs.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "valsartan",
        "name": "Valsartan",
        "pharmacologicClass": "angiotensin-receptor-blockers",
        "therapeuticClass": "antihypertensives",
        "system": "cardiovascular-system",
        "mechanism": "Block AT1 receptors, preventing angiotensin II effects without affecting bradykinin.",
        "features": "Proven mortality benefit in HF.",
        "clinicalChoice": "Heart failure with ACE inhibitor intolerance.",
        "indications": [
            "Hypertension",
            "Heart Failure"
        ],
        "contraindications": [
            "Pregnancy"
        ],
        "sideEffects": [
            "Hyperkalemia",
            "Hypotension",
            "Dizziness"
        ],
        "interactions": "Potassium-sparing diuretics, NSAIDs.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "irbesartan",
        "name": "Irbesartan",
        "pharmacologicClass": "angiotensin-receptor-blockers",
        "therapeuticClass": "antihypertensives",
        "system": "cardiovascular-system",
        "mechanism": "Block AT1 receptors, preventing angiotensin II effects without affecting bradykinin.",
        "features": "Excellent renal protection.",
        "clinicalChoice": "Diabetic nephropathy protection.",
        "indications": [
            "Hypertension",
            "Diabetic Nephropathy"
        ],
        "contraindications": [
            "Pregnancy"
        ],
        "sideEffects": [
            "Hyperkalemia",
            "Hypotension",
            "Dizziness"
        ],
        "interactions": "Potassium-sparing diuretics, NSAIDs.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "hydralazine",
        "name": "Hydralazine",
        "pharmacologicClass": "direct-vasodilators",
        "therapeuticClass": "antihypertensives",
        "system": "cardiovascular-system",
        "mechanism": "Directly relax arteriolar smooth muscle to reduce afterload (± preload).",
        "features": "Increases cGMP -> smooth muscle relaxation.",
        "clinicalChoice": "Severe HTN, HF (with nitrates) in pregnancy or AA patients.",
        "indications": [
            "Severe Hypertension",
            "Heart Failure"
        ],
        "contraindications": [
            "Coronary Artery Disease",
            "Rheumatic Heart Disease in Mitral Stenosis"
        ],
        "sideEffects": [
            "Reflex tachycardia",
            "Fluid retention",
            "Headache",
            "Hypertrichosis (minoxidil)"
        ],
        "interactions": "Often require concomitant β-blocker/diuretic to blunt reflex responses.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "minoxidil",
        "name": "Minoxidil",
        "pharmacologicClass": "direct-vasodilators",
        "therapeuticClass": "antihypertensives",
        "system": "cardiovascular-system",
        "mechanism": "Directly relax arteriolar smooth muscle to reduce afterload (± preload).",
        "features": "Opens K+ channels -> hyperpolarization.",
        "clinicalChoice": "Refractory hypertension, topical for alopecia.",
        "indications": [
            "Refractory Hypertension",
            "Alopecia"
        ],
        "contraindications": [
            "Pheochromocytoma"
        ],
        "sideEffects": [
            "Reflex tachycardia",
            "Fluid retention",
            "Headache",
            "Hypertrichosis (minoxidil)"
        ],
        "interactions": "Often require concomitant β-blocker/diuretic to blunt reflex responses.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "sodium-nitroprusside",
        "name": "Sodium Nitroprusside",
        "pharmacologicClass": "hypertensive-emergency-agents",
        "therapeuticClass": "antihypertensives",
        "system": "cardiovascular-system",
        "mechanism": "Rapidly lower blood pressure via potent arterial dilatation and renal vasodilation.",
        "features": "IV, short acting, releases NO and cyanide.",
        "clinicalChoice": "Hypertensive emergencies with acute target-organ damage.",
        "indications": [
            "Hypertensive Emergency"
        ],
        "contraindications": [
            "Renal Failure without thiosulfate"
        ],
        "sideEffects": [
            "Hypotension",
            "Cyanide toxicity (nitroprusside)",
            "Tachycardia",
            "Nausea"
        ],
        "interactions": "Additive hypotension with other vasodilators.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "fenoldopam",
        "name": "Fenoldopam",
        "pharmacologicClass": "hypertensive-emergency-agents",
        "therapeuticClass": "antihypertensives",
        "system": "cardiovascular-system",
        "mechanism": "Rapidly lower blood pressure via potent arterial dilatation and renal vasodilation.",
        "features": "D1 agonist -> renal vasodilation, natriuresis.",
        "clinicalChoice": "Hypertensive emergency with acute kidney injury.",
        "indications": [
            "Hypertensive Emergency",
            "Postoperative Hypertension"
        ],
        "contraindications": [
            "Sulfite Sensitivity"
        ],
        "sideEffects": [
            "Hypotension",
            "Cyanide toxicity (nitroprusside)",
            "Tachycardia",
            "Nausea"
        ],
        "interactions": "Additive hypotension with other vasodilators.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "amlodipine",
        "name": "Amlodipine",
        "pharmacologicClass": "calcium-channel-blockers",
        "therapeuticClass": "antihypertensives",
        "system": "cardiovascular-system",
        "mechanism": "Block L-type calcium channels, causing vasodilation or reduced cardiac contractility.",
        "features": "Long-acting dihydropyridine.",
        "clinicalChoice": "Hypertension with minimal cardiac effects.",
        "indications": [
            "Hypertension",
            "Angina"
        ],
        "contraindications": [
            "Severe Aortic Stenosis"
        ],
        "sideEffects": [
            "Peripheral edema",
            "Constipation",
            "Bradycardia"
        ],
        "interactions": "Beta-blockers (increased risk of heart block).",
        "interactionDetails": "BETA-BLOCKERS: MECHANISM - Non-dihydropyridine CCBs (verapamil, diltiazem) have negative chronotropic and dromotropic effects on the AV node. Beta-blockers also slow AV node conduction and reduce heart rate. CONSEQUENCE - Combined use significantly increases risk of symptomatic bradycardia, AV block (first-, second-, or third-degree), and potential asystole, especially in elderly patients or those with pre-existing conduction abnormalities.",
        "pageType": "drug"
    },
    {
        "id": "nifedipine",
        "name": "Nifedipine",
        "pharmacologicClass": "calcium-channel-blockers",
        "therapeuticClass": "antihypertensives",
        "system": "cardiovascular-system",
        "mechanism": "Block L-type calcium channels, causing vasodilation or reduced cardiac contractility.",
        "features": "Short-acting, can cause reflex tachycardia. | Calcium channel blocker, oral administration.",
        "clinicalChoice": "Prinzmetal angina.",
        "indications": [
            "Angina",
            "Hypertension",
            "Preterm Labor"
        ],
        "contraindications": [
            "Acute MI"
        ],
        "sideEffects": [
            "Peripheral edema",
            "Constipation",
            "Bradycardia"
        ],
        "interactions": "Beta-blockers (increased risk of heart block).",
        "interactionDetails": "BETA-BLOCKERS: MECHANISM - Non-dihydropyridine CCBs (verapamil, diltiazem) have negative chronotropic and dromotropic effects on the AV node. Beta-blockers also slow AV node conduction and reduce heart rate. CONSEQUENCE - Combined use significantly increases risk of symptomatic bradycardia, AV block (first-, second-, or third-degree), and potential asystole, especially in elderly patients or those with pre-existing conduction abnormalities.",
        "pageType": "drug",
        "pharmacologicClasses": [
            "calcium-channel-blockers",
            "tocolytics"
        ]
    },
    {
        "id": "verapamil",
        "name": "Verapamil",
        "pharmacologicClass": "calcium-channel-blockers",
        "therapeuticClass": "antihypertensives",
        "system": "cardiovascular-system",
        "mechanism": "Block L-type calcium channels, causing vasodilation or reduced cardiac contractility.",
        "features": "Non-dihydropyridine, cardiac selective.",
        "clinicalChoice": "Hypertension with arrhythmias.",
        "indications": [
            "Hypertension",
            "SVT"
        ],
        "contraindications": [
            "Heart Block",
            "Heart Failure"
        ],
        "sideEffects": [
            "Peripheral edema",
            "Constipation",
            "Bradycardia"
        ],
        "interactions": "Beta-blockers (increased risk of heart block).",
        "interactionDetails": "BETA-BLOCKERS: MECHANISM - Non-dihydropyridine CCBs (verapamil, diltiazem) have negative chronotropic and dromotropic effects on the AV node. Beta-blockers also slow AV node conduction and reduce heart rate. CONSEQUENCE - Combined use significantly increases risk of symptomatic bradycardia, AV block (first-, second-, or third-degree), and potential asystole, especially in elderly patients or those with pre-existing conduction abnormalities.",
        "pageType": "drug"
    },
    {
        "id": "diltiazem",
        "name": "Diltiazem",
        "pharmacologicClass": "calcium-channel-blockers",
        "therapeuticClass": "antihypertensives",
        "system": "cardiovascular-system",
        "mechanism": "Block L-type calcium channels, causing vasodilation or reduced cardiac contractility.",
        "features": "Non-dihydropyridine, intermediate selectivity.",
        "clinicalChoice": "Hypertension with atrial fibrillation.",
        "indications": [
            "Hypertension",
            "Atrial Fibrillation"
        ],
        "contraindications": [
            "Heart Block",
            "Heart Failure"
        ],
        "sideEffects": [
            "Peripheral edema",
            "Constipation",
            "Bradycardia"
        ],
        "interactions": "Beta-blockers (increased risk of heart block).",
        "interactionDetails": "BETA-BLOCKERS: MECHANISM - Non-dihydropyridine CCBs (verapamil, diltiazem) have negative chronotropic and dromotropic effects on the AV node. Beta-blockers also slow AV node conduction and reduce heart rate. CONSEQUENCE - Combined use significantly increases risk of symptomatic bradycardia, AV block (first-, second-, or third-degree), and potential asystole, especially in elderly patients or those with pre-existing conduction abnormalities.",
        "pageType": "drug"
    },
    {
        "id": "nitroglycerin",
        "name": "Nitroglycerin",
        "pharmacologicClass": "nitrates",
        "therapeuticClass": "antihypertensives",
        "system": "cardiovascular-system",
        "mechanism": "Release nitric oxide, causing venous and arterial vasodilation.",
        "features": "Short-acting, sublingual or IV.",
        "clinicalChoice": "Acute angina, pulmonary edema.",
        "indications": [
            "Angina",
            "Acute MI",
            "Pulmonary Edema"
        ],
        "contraindications": [
            "Severe Aortic Stenosis",
            "Recent PDE5 Inhibitor Use"
        ],
        "sideEffects": [
            "Headache",
            "Hypotension",
            "Tolerance with continuous use"
        ],
        "interactions": "Sildenafil and other PDE5 inhibitors (severe hypotension).",
        "interactionDetails": "PDE5 INHIBITORS: MECHANISM - Nitrates increase cGMP levels through nitric oxide release. PDE5 inhibitors (sildenafil, tadalafil, vardenafil) prevent cGMP breakdown by inhibiting phosphodiesterase-5. CONSEQUENCE - Synergistic vasodilation leads to severe, potentially life-threatening hypotension that may not respond to fluids and requires vasopressors.",
        "pageType": "drug"
    },
    {
        "id": "isosorbide-mononitrate",
        "name": "Isosorbide Mononitrate",
        "pharmacologicClass": "nitrates",
        "therapeuticClass": "antihypertensives",
        "system": "cardiovascular-system",
        "mechanism": "Release nitric oxide, causing venous and arterial vasodilation.",
        "features": "Long-acting, once daily.",
        "clinicalChoice": "Angina prophylaxis.",
        "indications": [
            "Angina Prophylaxis"
        ],
        "contraindications": [
            "Severe Aortic Stenosis",
            "Recent PDE5 Inhibitor Use"
        ],
        "sideEffects": [
            "Headache",
            "Hypotension",
            "Tolerance with continuous use"
        ],
        "interactions": "Sildenafil and other PDE5 inhibitors (severe hypotension).",
        "interactionDetails": "PDE5 INHIBITORS: MECHANISM - Nitrates increase cGMP levels through nitric oxide release. PDE5 inhibitors (sildenafil, tadalafil, vardenafil) prevent cGMP breakdown by inhibiting phosphodiesterase-5. CONSEQUENCE - Synergistic vasodilation leads to severe, potentially life-threatening hypotension that may not respond to fluids and requires vasopressors.",
        "pageType": "drug"
    },
    {
        "id": "isosorbide-dinitrate",
        "name": "Isosorbide Dinitrate",
        "pharmacologicClass": "nitrates",
        "therapeuticClass": "antihypertensives",
        "system": "cardiovascular-system",
        "mechanism": "Release nitric oxide, causing venous and arterial vasodilation.",
        "features": "Intermediate-acting, requires conversion.",
        "clinicalChoice": "Heart failure with hydralazine.",
        "indications": [
            "Angina",
            "Heart Failure"
        ],
        "contraindications": [
            "Severe Aortic Stenosis",
            "Recent PDE5 Inhibitor Use"
        ],
        "sideEffects": [
            "Headache",
            "Hypotension",
            "Tolerance with continuous use"
        ],
        "interactions": "Sildenafil and other PDE5 inhibitors (severe hypotension).",
        "interactionDetails": "PDE5 INHIBITORS: MECHANISM - Nitrates increase cGMP levels through nitric oxide release. PDE5 inhibitors (sildenafil, tadalafil, vardenafil) prevent cGMP breakdown by inhibiting phosphodiesterase-5. CONSEQUENCE - Synergistic vasodilation leads to severe, potentially life-threatening hypotension that may not respond to fluids and requires vasopressors.",
        "pageType": "drug"
    },
    {
        "id": "furosemide",
        "name": "Furosemide",
        "pharmacologicClass": "loop-diuretics",
        "therapeuticClass": "diuretics-cardiovascular",
        "systems": ["cardiovascular-system", "renal-genitourinary-system"],
        "mechanism": "Inhibit NKCC2 transporter in thick ascending limb, causing rapid fluid loss.",
        "features": "Most commonly used, IV/PO. | Most commonly used loop diuretic.",
        "clinicalChoice": "Acute heart failure, pulmonary edema.",
        "indications": [
            "Edema",
            "Heart Failure",
            "Hypertension",
            "Pulmonary Edema"
        ],
        "contraindications": [
            "Anuria",
            "Sulfonamide Allergy"
        ],
        "sideEffects": [
            "Hypokalemia",
            "Hyponatremia",
            "Ototoxicity"
        ],
        "interactions": "Aminoglycosides (ototoxicity), lithium (increased levels).",
        "interactionDetails": "AMINOGLYCOSIDES: MECHANISM - Both loop diuretics and aminoglycosides have direct ototoxic effects on hair cells in the cochlea. CONSEQUENCE - Synergistic permanent hearing loss. LITHIUM: MECHANISM - Volume depletion increases lithium reabsorption. CONSEQUENCE - Lithium toxicity with tremor and confusion.",
        "pageType": "drug",
        "pharmacologicClasses": [
            "loop-diuretics"
        ]
    },
    {
        "id": "bumetanide",
        "name": "Bumetanide",
        "pharmacologicClass": "loop-diuretics",
        "therapeuticClass": "diuretics-cardiovascular",
        "systems": ["cardiovascular-system", "renal-genitourinary-system"],
        "mechanism": "Inhibit NKCC2 transporter in thick ascending limb, causing rapid fluid loss.",
        "features": "40x more potent than furosemide.",
        "clinicalChoice": "Furosemide resistance.",
        "indications": [
            "Edema",
            "Heart Failure",
            "Hypertension"
        ],
        "contraindications": [
            "Anuria",
            "Sulfonamide Allergy"
        ],
        "sideEffects": [
            "Hypokalemia",
            "Hyponatremia",
            "Ototoxicity"
        ],
        "interactions": "Aminoglycosides (ototoxicity), lithium (increased levels).",
        "interactionDetails": "AMINOGLYCOSIDES: MECHANISM - Both loop diuretics and aminoglycosides have direct ototoxic effects on hair cells in the cochlea. CONSEQUENCE - Synergistic permanent hearing loss. LITHIUM: MECHANISM - Volume depletion increases lithium reabsorption. CONSEQUENCE - Lithium toxicity with tremor and confusion.",
        "pageType": "drug",
        "pharmacologicClasses": [
            "loop-diuretics"
        ]
    },
    {
        "id": "hydrochlorothiazide-hctz",
        "name": "Hydrochlorothiazide (HCTZ)",
        "pharmacologicClass": "thiazide-diuretics",
        "therapeuticClass": "diuretics-cardiovascular",
        "system": "cardiovascular-system",
        "mechanism": "Inhibit NCC transporter in distal convoluted tubule, first-line for HTN.",
        "features": "Most common thiazide.",
        "clinicalChoice": "First-line hypertension.",
        "indications": [
            "Edema",
            "Hypertension",
            "Mild Heart Failure"
        ],
        "contraindications": [
            "Anuria",
            "Sulfonamide Allergy"
        ],
        "sideEffects": [
            "Hypokalemia",
            "Hyperuricemia",
            "Hyperglycemia"
        ],
        "interactions": "Lithium (increased levels), NSAIDs (reduced efficacy).",
        "interactionDetails": "LITHIUM: MECHANISM - Thiazides cause volume depletion, increasing lithium reabsorption. CONSEQUENCE - Lithium toxicity. NSAIDS: MECHANISM - Thiazides work partly through prostaglandin-mediated vasodilation, NSAIDs block this. CONSEQUENCE - Reduced antihypertensive effect.",
        "pageType": "drug",
        "pharmacologicClasses": [
            "thiazide-diuretics"
        ]
    },
    {
        "id": "chlorthalidone",
        "name": "Chlorthalidone",
        "pharmacologicClass": "thiazide-diuretics",
        "therapeuticClass": "diuretics-cardiovascular",
        "systems": ["cardiovascular-system", "renal-genitourinary-system"],
        "mechanism": "Inhibit NCC transporter in distal convoluted tubule, first-line for HTN.",
        "features": "Longer half-life, better outcomes. | Longer half-life than HCTZ.",
        "clinicalChoice": "Preferred thiazide for HTN.",
        "indications": [
            "Hypertension"
        ],
        "contraindications": [
            "Anuria",
            "Sulfonamide Allergy"
        ],
        "sideEffects": [
            "Hypokalemia",
            "Hyperuricemia",
            "Hyperglycemia"
        ],
        "interactions": "Lithium (increased levels), NSAIDs (reduced efficacy).",
        "interactionDetails": "LITHIUM: MECHANISM - Thiazides cause volume depletion, increasing lithium reabsorption. CONSEQUENCE - Lithium toxicity. NSAIDS: MECHANISM - Thiazides work partly through prostaglandin-mediated vasodilation, NSAIDs block this. CONSEQUENCE - Reduced antihypertensive effect.",
        "pageType": "drug",
        "pharmacologicClasses": [
            "thiazide-diuretics"
        ]
    },
    {
        "id": "spironolactone",
        "name": "Spironolactone",
        "pharmacologicClass": "potassium-sparing-diuretics",
        "therapeuticClass": "diuretics-cardiovascular",
        "systems": ["cardiovascular-system", "renal-genitourinary-system"],
        "mechanism": "Block aldosterone receptors or ENaC channels, prevent K+ loss.",
        "features": "Aldosterone antagonist. | Aldosterone receptor antagonist.",
        "clinicalChoice": "Heart failure, prevents K+ loss.",
        "indications": [
            "Heart Failure",
            "Hirsutism",
            "Hypertension",
            "Primary Aldosteronism"
        ],
        "contraindications": [
            "Hyperkalemia",
            "Anuria"
        ],
        "sideEffects": [
            "Hyperkalemia",
            "Gynecomastia (spironolactone)"
        ],
        "interactions": "ACE inhibitors, ARBs (hyperkalemia).",
        "interactionDetails": "ACE INHIBITORS/ARBS: MECHANISM - Both reduce aldosterone and block potassium excretion. CONSEQUENCE - Dangerous hyperkalemia with risk of fatal arrhythmias.",
        "pageType": "drug",
        "pharmacologicClasses": [
            "potassium-sparing-diuretics"
        ]
    },
    {
        "id": "eplerenone",
        "name": "Eplerenone",
        "pharmacologicClass": "potassium-sparing-diuretics",
        "therapeuticClass": "diuretics-cardiovascular",
        "systems": ["cardiovascular-system", "renal-genitourinary-system"],
        "mechanism": "Block aldosterone receptors or ENaC channels, prevent K+ loss.",
        "features": "Selective aldosterone antagonist.",
        "clinicalChoice": "Post-MI heart failure.",
        "indications": [
            "Hypertension",
            "Post-MI Heart Failure"
        ],
        "contraindications": [
            "Hyperkalemia"
        ],
        "sideEffects": [
            "Hyperkalemia",
            "Gynecomastia (spironolactone)"
        ],
        "interactions": "ACE inhibitors, ARBs (hyperkalemia).",
        "interactionDetails": "ACE INHIBITORS/ARBS: MECHANISM - Both reduce aldosterone and block potassium excretion. CONSEQUENCE - Dangerous hyperkalemia with risk of fatal arrhythmias.",
        "pageType": "drug",
        "pharmacologicClasses": [
            "potassium-sparing-diuretics"
        ]
    },
    {
        "id": "quinidine-ia",
        "name": "Quinidine (IA)",
        "pharmacologicClass": "class-i-sodium-channel-blockers",
        "therapeuticClass": "antiarrhythmics",
        "system": "cardiovascular-system",
        "mechanism": "Block sodium channels, slowing conduction velocity. Sub-classified into IA, IB, IC based on effect on action potential duration.",
        "features": "Blocks Na+ and K+ channels.",
        "clinicalChoice": "Atrial fibrillation conversion.",
        "indications": [
            "Atrial Fibrillation",
            "Ventricular Arrhythmias"
        ],
        "contraindications": [
            "Heart Block",
            "Long QT"
        ],
        "sideEffects": [
            "Proarrhythmic effects",
            "CNS toxicity",
            "Anticholinergic effects"
        ],
        "interactions": "Many, due to effects on cardiac conduction and metabolism.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "procainamide-ia",
        "name": "Procainamide (IA)",
        "pharmacologicClass": "class-i-sodium-channel-blockers",
        "therapeuticClass": "antiarrhythmics",
        "system": "cardiovascular-system",
        "mechanism": "Block sodium channels, slowing conduction velocity. Sub-classified into IA, IB, IC based on effect on action potential duration.",
        "features": "Can cause drug-induced lupus.",
        "clinicalChoice": "Atrial and ventricular arrhythmias.",
        "indications": [
            "Atrial Arrhythmias",
            "Ventricular Arrhythmias"
        ],
        "contraindications": [
            "Heart Block",
            "Lupus"
        ],
        "sideEffects": [
            "Proarrhythmic effects",
            "CNS toxicity",
            "Anticholinergic effects"
        ],
        "interactions": "Many, due to effects on cardiac conduction and metabolism.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "lidocaine-ib",
        "name": "Lidocaine (IB)",
        "pharmacologicClass": "class-i-sodium-channel-blockers",
        "therapeuticClass": "antiarrhythmics",
        "system": "cardiovascular-system",
        "mechanism": "Block sodium channels, slowing conduction velocity. Sub-classified into IA, IB, IC based on effect on action potential duration.",
        "features": "Acts preferentially on ischemic tissue.",
        "clinicalChoice": "Ventricular arrhythmias post-MI.",
        "indications": [
            "Ventricular Arrhythmias"
        ],
        "contraindications": [
            "Heart Block"
        ],
        "sideEffects": [
            "Proarrhythmic effects",
            "CNS toxicity",
            "Anticholinergic effects"
        ],
        "interactions": "Many, due to effects on cardiac conduction and metabolism.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "flecainide-ic",
        "name": "Flecainide (IC)",
        "pharmacologicClass": "class-i-sodium-channel-blockers",
        "therapeuticClass": "antiarrhythmics",
        "system": "cardiovascular-system",
        "mechanism": "Block sodium channels, slowing conduction velocity. Sub-classified into IA, IB, IC based on effect on action potential duration.",
        "features": "Significant proarrhythmic potential.",
        "clinicalChoice": "Atrial fibrillation (pill-in-pocket).",
        "indications": [
            "Atrial Fibrillation"
        ],
        "contraindications": [
            "Structural Heart Disease",
            "CAD"
        ],
        "sideEffects": [
            "Proarrhythmic effects",
            "CNS toxicity",
            "Anticholinergic effects"
        ],
        "interactions": "Many, due to effects on cardiac conduction and metabolism.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "amiodarone",
        "name": "Amiodarone",
        "pharmacologicClass": "class-iii-potassium-channel-blockers",
        "therapeuticClass": "antiarrhythmics",
        "system": "cardiovascular-system",
        "mechanism": "Block potassium channels, prolonging repolarization and action potential duration.",
        "features": "Complex pharmacology, very long half-life.",
        "clinicalChoice": "Life-threatening arrhythmias.",
        "indications": [
            "Atrial Fibrillation",
            "Ventricular Arrhythmias"
        ],
        "contraindications": [
            "Iodine Allergy",
            "Heart Block"
        ],
        "sideEffects": [
            "QT prolongation",
            "Torsades de pointes",
            "Thyroid dysfunction"
        ],
        "interactions": "Drugs that prolong QT interval.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "sotalol",
        "name": "Sotalol",
        "pharmacologicClass": "class-iii-potassium-channel-blockers",
        "therapeuticClass": "antiarrhythmics",
        "system": "cardiovascular-system",
        "mechanism": "Block potassium channels, prolonging repolarization and action potential duration.",
        "features": "Combined beta-blocking and Class III effects.",
        "clinicalChoice": "Atrial fibrillation with rate control.",
        "indications": [
            "Atrial Fibrillation",
            "Ventricular Tachycardia"
        ],
        "contraindications": [
            "Asthma",
            "Long QT",
            "Heart Block"
        ],
        "sideEffects": [
            "QT prolongation",
            "Torsades de pointes",
            "Thyroid dysfunction"
        ],
        "interactions": "Drugs that prolong QT interval.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "adenosine",
        "name": "Adenosine",
        "pharmacologicClass": "miscellaneous-class-v",
        "therapeuticClass": "antiarrhythmics",
        "system": "cardiovascular-system",
        "mechanism": "Act through unique pathways to acutely slow AV node conduction or stabilize myocardium.",
        "features": "Very short acting, activates K+ efflux in AV node.",
        "clinicalChoice": "Acute supraventricular tachycardia conversion.",
        "indications": [
            "Paroxysmal SVT"
        ],
        "contraindications": [
            "Second/Third-Degree AV Block",
            "Asthma"
        ],
        "sideEffects": [
            "Flushing (adenosine)",
            "Chest discomfort",
            "Hypotension",
            "Bradycardia"
        ],
        "interactions": "Dipyridamole and carbamazepine potentiate adenosine; methylxanthines antagonize.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "magnesium-sulfate",
        "name": "Magnesium Sulfate",
        "pharmacologicClass": "miscellaneous-class-v",
        "therapeuticClass": "antiarrhythmics",
        "system": "cardiovascular-system",
        "mechanism": "Act through unique pathways to acutely slow AV node conduction or stabilize myocardium.",
        "features": "Stabilizes cardiac membrane, suppresses early afterdepolarizations.",
        "clinicalChoice": "Torsades de pointes, digoxin toxicity.",
        "indications": [
            "Torsades de Pointes",
            "Digoxin Toxicity"
        ],
        "contraindications": [
            "AV Block",
            "Renal Failure"
        ],
        "sideEffects": [
            "Flushing (adenosine)",
            "Chest discomfort",
            "Hypotension",
            "Bradycardia"
        ],
        "interactions": "Dipyridamole and carbamazepine potentiate adenosine; methylxanthines antagonize.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "atorvastatin",
        "name": "Atorvastatin",
        "pharmacologicClass": "statins",
        "therapeuticClass": "lipid-management",
        "system": "cardiovascular-system",
        "mechanism": "Inhibit HMG-CoA reductase, the rate-limiting step in cholesterol synthesis.",
        "features": "Most commonly prescribed.",
        "clinicalChoice": "First-line for hyperlipidemia.",
        "indications": [
            "Hyperlipidemia",
            "CAD Prevention"
        ],
        "contraindications": [
            "Active Liver Disease",
            "Pregnancy"
        ],
        "sideEffects": [
            "Myopathy",
            "Rhabdomyolysis",
            "Hepatotoxicity"
        ],
        "interactions": "CYP3A4 inhibitors increase levels.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "simvastatin",
        "name": "Simvastatin",
        "pharmacologicClass": "statins",
        "therapeuticClass": "lipid-management",
        "system": "cardiovascular-system",
        "mechanism": "Inhibit HMG-CoA reductase, the rate-limiting step in cholesterol synthesis.",
        "features": "More drug interactions.",
        "clinicalChoice": "Cost-effective option.",
        "indications": [
            "Hyperlipidemia"
        ],
        "contraindications": [
            "Active Liver Disease",
            "Pregnancy"
        ],
        "sideEffects": [
            "Myopathy",
            "Rhabdomyolysis",
            "Hepatotoxicity"
        ],
        "interactions": "CYP3A4 inhibitors increase levels.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "rosuvastatin",
        "name": "Rosuvastatin",
        "pharmacologicClass": "statins",
        "therapeuticClass": "lipid-management",
        "system": "cardiovascular-system",
        "mechanism": "Inhibit HMG-CoA reductase, the rate-limiting step in cholesterol synthesis.",
        "features": "Most potent statin.",
        "clinicalChoice": "High-intensity statin therapy.",
        "indications": [
            "Hyperlipidemia"
        ],
        "contraindications": [
            "Active Liver Disease",
            "Pregnancy"
        ],
        "sideEffects": [
            "Myopathy",
            "Rhabdomyolysis",
            "Hepatotoxicity"
        ],
        "interactions": "CYP3A4 inhibitors increase levels.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "pravastatin",
        "name": "Pravastatin",
        "pharmacologicClass": "statins",
        "therapeuticClass": "lipid-management",
        "system": "cardiovascular-system",
        "mechanism": "Inhibit HMG-CoA reductase, the rate-limiting step in cholesterol synthesis.",
        "features": "Hydrophilic, fewer interactions.",
        "clinicalChoice": "Multiple drug interactions concern.",
        "indications": [
            "Hyperlipidemia"
        ],
        "contraindications": [
            "Active Liver Disease",
            "Pregnancy"
        ],
        "sideEffects": [
            "Myopathy",
            "Rhabdomyolysis",
            "Hepatotoxicity"
        ],
        "interactions": "CYP3A4 inhibitors increase levels.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "ezetimibe",
        "name": "Ezetimibe",
        "pharmacologicClass": "cholesterol-absorption-inhibitors",
        "therapeuticClass": "lipid-management",
        "system": "cardiovascular-system",
        "mechanism": "Block NPC1L1 transporter at intestinal brush border to reduce cholesterol absorption.",
        "features": "Add-on for LDL reduction when statins insufficient.",
        "clinicalChoice": "Hyperlipidemia intolerant of high-dose statin.",
        "indications": [
            "Hyperlipidemia"
        ],
        "contraindications": [
            "Active Liver Disease"
        ],
        "sideEffects": [
            "Diarrhea",
            "Elevated LFTs (with statins)"
        ],
        "interactions": "Bile acid resins decrease ezetimibe absorption.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "cholestyramine",
        "name": "Cholestyramine",
        "pharmacologicClass": "bile-acid-sequestrants",
        "therapeuticClass": "lipid-management",
        "system": "cardiovascular-system",
        "mechanism": "Bind bile acids in intestine, forcing hepatic conversion of cholesterol to bile acids.",
        "features": "Powder formulation, lowers LDL modestly.",
        "clinicalChoice": "Hyperlipidemia in patients intolerant to statins.",
        "indications": [
            "Hyperlipidemia",
            "Pruritus from Cholestasis"
        ],
        "contraindications": [
            "Complete Biliary Obstruction"
        ],
        "sideEffects": [
            "GI distress",
            "Decreased fat-soluble vitamins"
        ],
        "interactions": "Reduce absorption of many drugs (digoxin, warfarin).",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "colesevelam",
        "name": "Colesevelam",
        "pharmacologicClass": "bile-acid-sequestrants",
        "therapeuticClass": "lipid-management",
        "system": "cardiovascular-system",
        "mechanism": "Bind bile acids in intestine, forcing hepatic conversion of cholesterol to bile acids.",
        "features": "Tablet, better tolerated.",
        "clinicalChoice": "Adjunct LDL lowering with fewer GI effects.",
        "indications": [
            "Hyperlipidemia"
        ],
        "contraindications": [
            "Triglycerides >500 mg/dL"
        ],
        "sideEffects": [
            "GI distress",
            "Decreased fat-soluble vitamins"
        ],
        "interactions": "Reduce absorption of many drugs (digoxin, warfarin).",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "gemfibrozil",
        "name": "Gemfibrozil",
        "pharmacologicClass": "fibrates",
        "therapeuticClass": "lipid-management",
        "system": "cardiovascular-system",
        "mechanism": "Activate PPAR-α to increase lipoprotein lipase activity and lower triglycerides.",
        "features": "Potent TG lowering.",
        "clinicalChoice": "Severe hypertriglyceridemia to prevent pancreatitis.",
        "indications": [
            "Hypertriglyceridemia"
        ],
        "contraindications": [
            "Gallbladder Disease",
            "Severe Renal/Hepatic Dysfunction"
        ],
        "sideEffects": [
            "Myopathy (especially with statins)",
            "Gallstones"
        ],
        "interactions": "Gemfibrozil increases statin levels via OATP inhibition.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "fenofibrate",
        "name": "Fenofibrate",
        "pharmacologicClass": "fibrates",
        "therapeuticClass": "lipid-management",
        "system": "cardiovascular-system",
        "mechanism": "Activate PPAR-α to increase lipoprotein lipase activity and lower triglycerides.",
        "features": "Safer with statins, once-daily.",
        "clinicalChoice": "Hypertriglyceridemia with mixed dyslipidemia.",
        "indications": [
            "Hypertriglyceridemia"
        ],
        "contraindications": [
            "Severe Renal Impairment"
        ],
        "sideEffects": [
            "Myopathy (especially with statins)",
            "Gallstones"
        ],
        "interactions": "Gemfibrozil increases statin levels via OATP inhibition.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "niacin-vitamin-b3",
        "name": "Niacin (Vitamin B3)",
        "pharmacologicClass": "niacin",
        "therapeuticClass": "lipid-management",
        "system": "cardiovascular-system",
        "mechanism": "Inhibits hepatic VLDL synthesis and adipose lipolysis, raising HDL.",
        "features": "Most effective agent for raising HDL.",
        "clinicalChoice": "Combined dyslipidemia with low HDL.",
        "indications": [
            "Mixed Dyslipidemia"
        ],
        "contraindications": [
            "Gout",
            "Active Peptic Ulcer Disease"
        ],
        "sideEffects": [
            "Flushing",
            "Hyperglycemia",
            "Hyperuricemia",
            "Hepatotoxicity"
        ],
        "interactions": "Additive myopathy with statins.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "digoxin",
        "name": "Digoxin",
        "pharmacologicClass": "cardiac-glycosides",
        "therapeuticClass": "positive-inotropes",
        "system": "cardiovascular-system",
        "mechanism": "Inhibit Na+/K+-ATPase pump, increasing intracellular calcium and cardiac contractility.",
        "features": "Narrow therapeutic window, requires monitoring.",
        "clinicalChoice": "Atrial fibrillation rate control, heart failure.",
        "indications": [
            "Atrial Fibrillation",
            "Heart Failure"
        ],
        "contraindications": [
            "Ventricular Arrhythmias",
            "Hypertrophic Cardiomyopathy"
        ],
        "sideEffects": [
            "Arrhythmias",
            "Nausea",
            "Visual disturbances",
            "Confusion"
        ],
        "interactions": "Diuretics (hypokalemia increases toxicity), amiodarone, quinidine.",
        "interactionDetails": "DIURETICS: MECHANISM - Digoxin toxicity is potentiated by hypokalemia because potassium competes with digoxin for binding to Na+/K+-ATPase. CONSEQUENCE - Low potassium increases digoxin binding and toxicity, leading to dangerous arrhythmias. AMIODARONE/QUINIDINE: MECHANISM - These drugs inhibit P-glycoprotein, reducing digoxin clearance. CONSEQUENCE - Increased digoxin levels requiring dose reduction.",
        "pageType": "drug"
    },
    {
        "id": "milrinone",
        "name": "Milrinone",
        "pharmacologicClass": "phosphodiesterase-3-inhibitors",
        "therapeuticClass": "positive-inotropes",
        "system": "cardiovascular-system",
        "mechanism": "Inhibit PDE3 to increase cAMP in cardiomyocytes and vascular smooth muscle, enhancing inotropy and vasodilation.",
        "features": "IV inotrope with vasodilatory properties.",
        "clinicalChoice": "Acute decompensated heart failure with low output.",
        "indications": [
            "Acute Heart Failure"
        ],
        "contraindications": [
            "Severe Valvular Disease"
        ],
        "sideEffects": [
            "Arrhythmias",
            "Hypotension",
            "Thrombocytopenia"
        ],
        "interactions": "Additive hypotension with other vasodilators.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "evolocumab",
        "name": "Evolocumab",
        "pharmacologicClass": "pcsk9-inhibitors",
        "therapeuticClass": "lipid-lowering-agents",
        "system": "cardiovascular-system",
        "mechanism": "Monoclonal antibody that inhibits PCSK9, preventing degradation of LDL receptors and increasing hepatic LDL clearance.",
        "features": "Injectable biologic, dramatically lowers LDL-C (50-60%).",
        "clinicalChoice": "Familial hypercholesterolemia, statin-intolerant patients, high CV risk despite maximally tolerated statin.",
        "indications": [
            "Familial Hypercholesterolemia",
            "Atherosclerotic Cardiovascular Disease (statin inadequate)",
            "Statin Intolerance"
        ],
        "contraindications": [
            "Hypersensitivity to evolocumab"
        ],
        "sideEffects": [
            "Injection site reactions",
            "Myalgias",
            "Upper respiratory infections",
            "Nasopharyngitis"
        ],
        "interactions": "Minimal drug interactions (monoclonal antibody).",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "alirocumab",
        "name": "Alirocumab",
        "pharmacologicClass": "pcsk9-inhibitors",
        "therapeuticClass": "lipid-lowering-agents",
        "system": "cardiovascular-system",
        "mechanism": "Monoclonal antibody that inhibits PCSK9, preventing degradation of LDL receptors and increasing hepatic LDL clearance.",
        "features": "Injectable biologic, alternative PCSK9 inhibitor to evolocumab.",
        "clinicalChoice": "Similar to evolocumab - familial hypercholesterolemia, high CV risk.",
        "indications": [
            "Familial Hypercholesterolemia",
            "Atherosclerotic Cardiovascular Disease (statin inadequate)"
        ],
        "contraindications": [
            "Hypersensitivity to alirocumab"
        ],
        "sideEffects": [
            "Injection site reactions",
            "Myalgias",
            "Upper respiratory infections",
            "Flu-like symptoms"
        ],
        "interactions": "Minimal drug interactions (monoclonal antibody).",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "icosapent-ethyl",
        "name": "Icosapent Ethyl (Vascepa)",
        "pharmacologicClass": "omega-3-fatty-acids",
        "therapeuticClass": "lipid-lowering-agents",
        "system": "cardiovascular-system",
        "mechanism": "Purified EPA (eicosapentaenoic acid) reduces triglyceride synthesis and increases fatty acid oxidation.",
        "features": "Pure EPA (not mixed omega-3), proven CV outcomes benefit.",
        "clinicalChoice": "Hypertriglyceridemia with established CVD or diabetes plus risk factors, on statin therapy.",
        "indications": [
            "Hypertriglyceridemia (>150 mg/dL) with CVD or diabetes",
            "Cardiovascular Risk Reduction"
        ],
        "contraindications": [
            "Fish or shellfish allergy"
        ],
        "sideEffects": [
            "Atrial fibrillation (increased risk)",
            "Bleeding (minor)",
            "Musculoskeletal pain"
        ],
        "interactions": "Anticoagulants/antiplatelets (increased bleeding risk).",
        "interactionDetails": "ANTICOAGULANTS/ANTIPLATELETS: MECHANISM - Omega-3 fatty acids have mild antiplatelet effects by reducing thromboxane A2 production. CONSEQUENCE - Additive bleeding risk with warfarin, DOACs, aspirin, or clopidogrel. Monitor for bleeding.",
        "pageType": "drug"
    },
    {
        "id": "sacubitril-valsartan",
        "name": "Sacubitril/Valsartan (Entresto)",
        "pharmacologicClass": "arni",
        "therapeuticClass": "heart-failure",
        "system": "cardiovascular-system",
        "mechanism": "Combination: Sacubitril (neprilysin inhibitor) increases natriuretic peptides + Valsartan (ARB) blocks angiotensin II.",
        "features": "First ARNI, superior to ACE-I in HFrEF, reduces CV death and hospitalizations.",
        "clinicalChoice": "HFrEF (EF ≤40%) to replace ACE-I/ARB, NYHA class II-IV.",
        "indications": [
            "Heart Failure with Reduced Ejection Fraction (HFrEF)"
        ],
        "contraindications": [
            "Concomitant ACE-I (angioedema risk - 36hr washout required)",
            "History of angioedema",
            "Pregnancy"
        ],
        "sideEffects": [
            "Hypotension",
            "Hyperkalemia",
            "Renal dysfunction",
            "Angioedema (rare but serious)",
            "Cough (less than ACE-I)"
        ],
        "interactions": "ACE inhibitors (do NOT use together - angioedema risk), potassium-sparing diuretics (hyperkalemia).",
        "interactionDetails": "ACE INHIBITORS: MECHANISM - Both neprilysin inhibitors and ACE inhibitors increase bradykinin levels. Neprilysin degrades bradykinin; ACE-I prevents bradykinin breakdown. CONSEQUENCE - Severe angioedema risk. Require 36-hour washout after stopping ACE-I before starting sacubitril/valsartan. POTASSIUM-SPARING DIURETICS: MECHANISM - ARB component reduces aldosterone, neprilysin inhibition increases ANP/BNP (promote natriuresis but can affect potassium). CONSEQUENCE - Hyperkalemia risk, especially with K-sparing diuretics or K supplements.",
        "pageType": "drug"
    },
    {
        "id": "ivabradine",
        "name": "Ivabradine",
        "pharmacologicClass": "if-channel-blockers",
        "therapeuticClass": "heart-failure",
        "system": "cardiovascular-system",
        "mechanism": "Selectively inhibits If (funny current) channels in SA node, reducing heart rate without affecting contractility.",
        "features": "Pure heart rate reducer, no effect on blood pressure or contractility.",
        "clinicalChoice": "HFrEF (EF ≤35%) in sinus rhythm with HR ≥70 despite beta-blocker, or beta-blocker intolerant.",
        "indications": [
            "Heart Failure with Reduced Ejection Fraction",
            "Stable Angina (Europe)"
        ],
        "contraindications": [
            "Resting HR <60 bpm",
            "Sick sinus syndrome",
            "AV block",
            "Atrial fibrillation"
        ],
        "sideEffects": [
            "Bradycardia",
            "Phosphenes (visual brightness, 15%)",
            "Blurred vision",
            "Atrial fibrillation"
        ],
        "interactions": "CYP3A4 inhibitors (increase ivabradine levels - bradycardia risk), other negative chronotropes (additive bradycardia).",
        "interactionDetails": "CYP3A4 INHIBITORS: MECHANISM - Ivabradine is metabolized by CYP3A4. Strong inhibitors (ketoconazole, clarithromycin, grapefruit juice) increase ivabradine levels. CONSEQUENCE - Excessive bradycardia. Avoid strong CYP3A4 inhibitors. NEGATIVE CHRONOTROPES: MECHANISM - Additive heart rate lowering with beta-blockers, digoxin, diltiazem, verapamil. CONSEQUENCE - Severe bradycardia or heart block. Use cautiously with appropriate monitoring.",
        "pageType": "drug"
    },
    {
        "id": "ranolazine",
        "name": "Ranolazine",
        "pharmacologicClass": "late-sodium-channel-blockers",
        "therapeuticClass": "antianginals",
        "system": "cardiovascular-system",
        "mechanism": "Inhibits late sodium current in cardiomyocytes, reducing intracellular calcium overload and improving diastolic relaxation.",
        "features": "Antianginal without affecting heart rate or blood pressure.",
        "clinicalChoice": "Chronic stable angina refractory to other antianginals (add-on therapy).",
        "indications": [
            "Chronic Stable Angina (refractory)"
        ],
        "contraindications": [
            "QT prolongation",
            "Cirrhosis",
            "Strong CYP3A4 inhibitors"
        ],
        "sideEffects": [
            "QT prolongation",
            "Dizziness",
            "Constipation",
            "Nausea",
            "Headache"
        ],
        "interactions": "CYP3A4 inhibitors/inducers (alter ranolazine levels), QT-prolonging drugs, digoxin (increases digoxin levels).",
        "interactionDetails": "CYP3A4 INHIBITORS: MECHANISM - Ranolazine is metabolized by CYP3A4. Inhibitors increase ranolazine levels. CONSEQUENCE - QT prolongation, arrhythmia risk. Contraindicated with strong inhibitors. DIGOXIN: MECHANISM - Ranolazine inhibits P-glycoprotein, reducing digoxin clearance. CONSEQUENCE - Increased digoxin levels and toxicity. Monitor digoxin levels, consider dose reduction.",
        "pageType": "drug"
    },
    {
        "id": "carvedilol",
        "name": "Carvedilol",
        "pharmacologicClass": "beta-blockers",
        "therapeuticClass": "heart-failure",
        "systems": ["cardiovascular-system"],
        "mechanism": "Non-selective beta-blocker (β1, β2) with additional alpha-1 blocking properties, providing vasodilation.",
        "features": "Beta-blocker with alpha-blocking (vasodilation), proven mortality benefit in HF.",
        "clinicalChoice": "Heart failure (HFrEF), hypertension, post-MI.",
        "indications": [
            "Heart Failure with Reduced Ejection Fraction",
            "Hypertension",
            "Post-Myocardial Infarction"
        ],
        "contraindications": [
            "Decompensated heart failure",
            "Severe bradycardia",
            "AV block",
            "Asthma/COPD (relative)"
        ],
        "sideEffects": [
            "Bradycardia",
            "Hypotension (more than selective beta-blockers)",
            "Fatigue",
            "Dizziness",
            "Weight gain"
        ],
        "interactions": "Verapamil/diltiazem (severe bradycardia), insulin (masks hypoglycemia), CYP2D6 interactions.",
        "interactionDetails": "CALCIUM CHANNEL BLOCKERS: MECHANISM - Both carvedilol and non-dihydropyridine CCBs (verapamil, diltiazem) have negative chronotropic and inotropic effects. CONSEQUENCE - Severe bradycardia, heart block, hypotension, or heart failure exacerbation. INSULIN/ORAL HYPOGLYCEMICS: MECHANISM - Beta-blockade masks sympathetic symptoms of hypoglycemia (tachycardia, tremor) and impairs glycogenolysis. CONSEQUENCE - Prolonged hypoglycemia without typical warning signs. Monitor glucose closely.",
        "pageType": "drug"
    },
    {
        "id": "clonidine",
        "name": "Clonidine",
        "pharmacologicClass": "central-alpha-2-agonists",
        "therapeuticClass": "antihypertensives",
        "systems": ["cardiovascular-system", "nervous-system"],
        "mechanism": "Central alpha-2 adrenergic agonist that decreases sympathetic outflow from CNS, reducing peripheral vascular resistance and heart rate.",
        "features": "Central-acting antihypertensive, also used for ADHD, opioid/alcohol withdrawal.",
        "clinicalChoice": "Hypertensive urgency, ADHD (non-stimulant), opioid withdrawal symptoms.",
        "indications": [
            "Hypertension",
            "Hypertensive Urgency",
            "ADHD",
            "Opioid Withdrawal",
            "Alcohol Withdrawal"
        ],
        "contraindications": [
            "Hypersensitivity to clonidine"
        ],
        "sideEffects": [
            "Dry mouth (very common)",
            "Sedation/drowsiness",
            "Orthostatic hypotension",
            "Rebound hypertension (abrupt discontinuation - DANGEROUS)",
            "Bradycardia",
            "Constipation",
            "Depression"
        ],
        "interactions": "Beta-blockers (severe bradycardia), TCAs (reduce clonidine efficacy), CNS depressants (additive sedation).",
        "interactionDetails": "BETA-BLOCKERS: MECHANISM - Both clonidine and beta-blockers reduce heart rate through different mechanisms. Clonidine via central sympathetic suppression, beta-blockers via peripheral blockade. CONSEQUENCE - Severe bradycardia, heart block. If discontinuing clonidine with concurrent beta-blocker, STOP BETA-BLOCKER FIRST, then taper clonidine to avoid rebound hypertension. TRICYCLIC ANTIDEPRESSANTS: MECHANISM - TCAs block alpha-2 receptors, antagonizing clonidine's effects. CONSEQUENCE - Reduced antihypertensive efficacy, hypertensive crisis risk. Avoid combination or use alternative antihypertensive.",
        "pageType": "drug"
    },
    {
        "id": "methyldopa",
        "name": "Methyldopa",
        "pharmacologicClass": "central-alpha-2-agonists",
        "therapeuticClass": "antihypertensives",
        "system": "cardiovascular-system",
        "mechanism": "Prodrug converted to alpha-methylnorepinephrine, a central alpha-2 agonist that decreases sympathetic outflow.",
        "features": "Pregnancy Category B - safe in pregnancy (drug of choice for chronic HTN in pregnancy).",
        "clinicalChoice": "Hypertension in pregnancy (first-line), chronic hypertension in patients where other agents contraindicated.",
        "indications": [
            "Hypertension in Pregnancy",
            "Chronic Hypertension"
        ],
        "contraindications": [
            "Active Hepatic Disease",
            "Pheochromocytoma",
            "MAOIs"
        ],
        "sideEffects": [
            "Positive direct Coombs test (10-20% - usually no hemolysis)",
            "Hemolytic anemia (rare but serious)",
            "Hepatotoxicity (monitor LFTs)",
            "Sedation",
            "Dry mouth",
            "Orthostatic hypotension",
            "Drug-induced lupus (rare)",
            "Sexual dysfunction"
        ],
        "interactions": "Iron supplements (reduce methyldopa absorption), MAOIs (hypertensive crisis), lithium (increased lithium toxicity).",
        "interactionDetails": "IRON SUPPLEMENTS: MECHANISM - Iron chelates methyldopa in GI tract, forming poorly absorbed complexes. CONSEQUENCE - Reduced methyldopa absorption and antihypertensive efficacy. Separate dosing by 2+ hours. MAOIS: MECHANISM - Both increase CNS catecholamine levels through different pathways. CONSEQUENCE - Hypertensive crisis, excitation, hallucinations. Contraindicated. LITHIUM: MECHANISM - Methyldopa may increase lithium levels or enhance lithium neurotoxicity. CONSEQUENCE - Lithium toxicity (tremor, confusion). Monitor lithium levels closely.",
        "pageType": "drug"
    },
    {
        "id": "ezetimibe",
        "name": "Ezetimibe",
        "pharmacologicClass": "cholesterol-absorption-inhibitors",
        "therapeuticClass": "lipid-lowering-agents",
        "system": "cardiovascular-system",
        "mechanism": "Inhibits NPC1L1 transporter in small intestine brush border, blocking dietary and biliary cholesterol absorption.",
        "features": "Unique mechanism (not a statin), additive with statins, lowers LDL ~18-20%.",
        "clinicalChoice": "Add-on to statin for LDL goal not met, statin intolerance, combination therapy (ezetimibe/simvastatin).",
        "indications": [
            "Primary Hyperlipidemia",
            "Familial Hypercholesterolemia",
            "Homozygous Sitosterolemia"
        ],
        "contraindications": [
            "Active Liver Disease (when combined with statin)",
            "Pregnancy (when combined with statin)"
        ],
        "sideEffects": [
            "Diarrhea",
            "Arthralgia/myalgia (mild)",
            "Upper respiratory infection",
            "Hepatotoxicity (rare, mainly with statin)",
            "Rhabdomyolysis (rare, mainly with statin)"
        ],
        "interactions": "Fibrates (increased risk of cholelithiasis), cyclosporine (increased ezetimibe levels), bile acid sequestrants (reduce ezetimibe absorption).",
        "interactionDetails": "FIBRATES: MECHANISM - Both ezetimibe and fibrates increase biliary cholesterol excretion and can promote gallstone formation. CONSEQUENCE - Increased risk of cholelithiasis. Use combination cautiously, monitor for gallstones. BILE ACID SEQUESTRANTS: MECHANISM - Cholestyramine and colestipol bind ezetimibe in intestine, reducing absorption. CONSEQUENCE - Decreased ezetimibe efficacy. Give ezetimibe at least 2 hours before or 4+ hours after bile acid sequestrant. CYCLOSPORINE: MECHANISM - Cyclosporine increases ezetimibe levels through unclear mechanism. CONSEQUENCE - Monitor for increased side effects. May need dose adjustment.",
        "pageType": "drug"
    }

];export default drugs;
